Everhart Financial Group Inc. Acquires 135,066 Shares of SELLAS Life Sciences Group, Inc. $SLS

Everhart Financial Group Inc. lifted its holdings in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by 40.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 466,216 shares of the company’s stock after purchasing an additional 135,066 shares during the period. Everhart Financial Group Inc. owned 0.33% of SELLAS Life Sciences Group worth $1,758,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of SELLAS Life Sciences Group by 2.8% during the 3rd quarter. Vanguard Group Inc. now owns 6,839,905 shares of the company’s stock worth $11,012,000 after purchasing an additional 185,106 shares in the last quarter. Anson Funds Management LP increased its position in SELLAS Life Sciences Group by 2,093.8% in the 3rd quarter. Anson Funds Management LP now owns 6,032,938 shares of the company’s stock valued at $9,713,000 after buying an additional 5,757,938 shares in the last quarter. Marshall Wace LLP increased its position in SELLAS Life Sciences Group by 23,550.0% in the 2nd quarter. Marshall Wace LLP now owns 2,715,489 shares of the company’s stock valued at $5,947,000 after buying an additional 2,704,007 shares in the last quarter. Geode Capital Management LLC raised its stake in SELLAS Life Sciences Group by 168.2% during the 2nd quarter. Geode Capital Management LLC now owns 2,200,428 shares of the company’s stock worth $4,819,000 after buying an additional 1,379,988 shares during the period. Finally, GSA Capital Partners LLP boosted its holdings in SELLAS Life Sciences Group by 21.7% in the third quarter. GSA Capital Partners LLP now owns 518,995 shares of the company’s stock worth $836,000 after acquiring an additional 92,411 shares in the last quarter. Institutional investors and hedge funds own 17.38% of the company’s stock.

SELLAS Life Sciences Group Stock Performance

Shares of SLS opened at $4.76 on Friday. SELLAS Life Sciences Group, Inc. has a 52-week low of $0.95 and a 52-week high of $6.14. The stock’s 50-day simple moving average is $4.45 and its 200 day simple moving average is $2.89. The stock has a market capitalization of $678.01 million, a price-to-earnings ratio of -19.04 and a beta of 2.18.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its quarterly earnings data on Thursday, March 19th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, research analysts forecast that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SLS. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Thursday, January 22nd. Maxim Group boosted their price target on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, March 12th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $10.00.

SELLAS Life Sciences Group Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.